Cipla and Stempeutics collaborate for launch of Stempeucel®, first 'Made in India' Cell Therapy to treat Critical Limb Ischemia (CLI)
- Written by PR Newswire Asia - News Pronto RSS
- First approved allogeneic cell therapy product globally for the treatment of CLI
- Developed by Stempeutics over a period of twelve years, breakthrough treatment designed to address root cause of the disease at an affordable cost
- Cipla to market and distribute the drug in India to provide patient access
 |
MUMBAI, India, Aug. 21, 2020 /PRNewswire/...